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Chet Kaczor, RPh, PharmD, MBA
Chet Kaczor is director of pharmacy services of Nationwide Children's Hospital in Columbus, Ohio.
Kaczor graduated from the Ohio Northern University Raabe College of Pharmacy in 2006 with his
doctor of pharmacy and then earned a master of business administration degree at The Ohio State
University Fisher College of Business in 2011. Since graduating from Ohio Northern University, Kaczor's
pharmacy experience has included being a manager of a Rite Aid Pharmacy, a regional director of operations at Pharmacy Systems, Inc., the manager of ambulatory pharmacy services at Nationwide Children's Hospital and, most recently, director of pharmacy services at Nationwide Children's Hospital.
Kaczor is involved in many professional organizations which include the Ohio Pharmacists Association
(OPA), of which he is the current president, the American Society of Health-System Pharmacists
(ASHP), the Ohio Society of Health-System Pharmacists (OSHP) and the Pediatric Pharmacy Advocacy
Group (PPAG). Kaczor's areas of interest in pharmacy include leadership, medication therapy management (MTM), strategic planning and pharmacy operations. In addition, Kaczor has served as a great
role model and preceptor for pharmacy students for advanced pharmacy practice experience rotations.

Chet Kaczor

Introducing the Issues
Based on the ASHP Pharmacy Forecast, Kaczor introduced predictions for the pharmacy profession regarding how specialty pharmaceuticals, pharmacogenomics, limited distribution systems, cost management of generic drugs and vertical integration of pharmaceutical
manufacturers will look in the next five years. These topics are very important in the pharmaceutical industry, and pharmacists should be
1
proactively thinking about challenges and corresponding solutions that may eventually arise in these areas.
In order to provide a framework for discussion among the Summit's participants, Kaczor first provided an overview of current issues. After
the summary, the Summit attendees, with a wide variety of pharmacy experiences and expertise, could then offer their thoughts and
leadership experiences to strategically plan and form future goals for these various issues. To achieve approval for a new drug in the
marketplace, the U.S. Food and Drug Administration (FDA} examines various characteristics of a drug such as its absorption, distribution,
metabolism, excretion, mechanism of action, dosage form, side effects, drug-drug interactions and effectiveness in comparison to similar
2
drugs. Kaczor provided some statistics on new drug approvals over the last couple years and noted that there were 41 new drug approvals in 2014 and 45 in 2015. Out of all these approvals, Kaczor emphasized that over 20 percent were oncology medications. The cost of
3
cancer treatment is also predicted to increase approximately 166 percent from 2006 to 2020. Additionally, there has been an increased
trend for cancer drugs to have indications for a specific cancer type, formulations to target specific biological markers for a more personalized treatment approach and chemotherapy by oral administration instead of traditional intravenous methods. The advancement of
oral cancer therapy can now allow patients to receive cancer therapy while at home, although similar side effects to that of intravenous
4
therapy may be present.
Regarding specialty pharmacy, Kaczor mentioned that there has been a 67 percent increase in the cost of specialty medications to treat
chronic diseases. Although there is not a standard definition for specialty medications, common characteristics include medications that
cost greater than $600 which have a complexity component including, but not limited to, chronic disease states, limited distribution systems, special storage conditions and ongoing safety and efficacy monitoring. Some disease states that require specialty pharmacy services
include oncology, multiple sclerosis, rheumatoid arthritis, Crohn's disease, human immunodeficiency virus/acquired immunodeficiency
5
syndrome (HIV/AIDS), hepatitis C and growth hormone disorders. When analyzing the overall medication costs in 2014, Kaczor noted
that around 32 percent of this cost was attributed to specialty medicines. Over the next few years, this amount is expected to further increase to around 50 percent.
To further provide a framework to generate discussion, Kaczor asked for thoughts on how pharmacists can take a leadership role within
pharmacogenomics. To emphasize the need to use a pharmacist's knowledge with pharmacogenomics, Kaczor focused on the pharmacogenomic effects with the antiplatelet drug clopidogrel. Regarding clopidogrel's metabolism, Kaczor explained that patients may be a
slow, regular or rapid metabolizer of the CYP2C19 enzyme. Without proper education on pharmacogenomic data, Kaczor noted that
some may assume a poor metabolizer for clopidogrel may cause increased levels of the drug; however, a poor metabolizer of this particular medication will actually cause less prodrug form to convert into its active form, likely contributing to subtherapeutic effects. To
further observe the complexity of pharmacogenomics, Kaczor then mentioned other factors that must also be included in making therapeutic decisions such as a patient's other medications that may either induce or inhibit the CYP2C19 enzyme. Kaczor also brought to
attention legal implications that affect the management of a patient's pharmacogenomic data. Since only a small portion of pharmacogenomic data is needed for drug interventions, Kaczor challenged how the remaining portion of pharmacogenomics data should be
handled.
Kaczor asked for thoughts on the incorporation of biosimilars into pharmacy practice since drugs such as Neupogen® (filgrastim) and
Remicade® (infliximab} are not considered bioequivalent like many generics. To provide an overview of the emergence of biosimilars to
the pharmaceutical marketplace, their approval process is somewhat similar to that of a generic small-molecule drug with its respective
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brand drug. To denote one important difference, a biosimilar drug does not have the exact chemical structure as its biologic predecessor,
unlike brand and generic small molecule drugs. Still, a biosimilar performs the same therapeutic action as its biologic predecessor, like
brand and generic small molecule drugs. With patents of various biologic reference drugs expiring soon, there will be an increased entrance of biosimilars into the marketplace with subsequent lower costs. With this new area of pharmacy, leadership will be needed to
6
address the regulation, legislation and formulary decisions with these new biosimilars.
Next, to address the escalation in generic drug prices in the pharmaceutical marketplace, Kaczor pointed out that there has been a 373
percent increase in the price of generic drugs from 2013 to 2014. As a reference point, he explained that this would equate to a drug that
costs $13 on average now costing around $60.
Kaczor then introduced the topic of limited distribution systems and asked for ideas to address the fragmented care that some of the
more complicated patients currently receive. Additionally, Kaczor asked for thoughts on eliminating risks from limited distribution systems and improving pharmacist leadership to advocate against these systems.
The last topic explored was the increased trend in both horizontal and vertical integration of pharmaceutical manufacturers. He defined
horizontal integration as the merging of multiple manufacturer companies and explained that vertical integration observes the entire
drug process from management of raw materials to distribution to hospitals.

Engaging the Audience: What are Goals and Strategies Associated with These Issues?
To initiate the group discussion of the Summit's participants, Kaczor first asked for thoughts to address limited distribution systems and
specialty pharmacy. One participant brought up the point that around 50 percent of all FDA drug approvals are currently being approved
as specialty pharmacy. Then, the participants questioned if all new drug approvals or even generics may eventually become classified as
specialty pharmacy since there is no industry standard to classify them. One Ohio Northern University alumnus offered some remarks
from a payer perspective regarding specialty pharmacy by mentioning that distribution systems are moving from fee-for-service to valuebased medicine. Currently, specialty pharmacies are based on a fee-for-service model more commonly than a value-based model. One
attendee remarked that over time he has been noticing a shift for limited distribution systems to follow Accountable Care Organizations
(ACOs). This will help pharmaceuticals to further transition into a value-based model in the future. To understand the purpose of an ACO,
it can be defined as a network of healthcare professionals and hospitals who work together to provide a better continuum and quality of
care for patients while sharing medical and financial responsibilities. The ACOs operate to provide the right services to the right patient at
78
the right time while reducing duplication in medical tests and other services. '
Some ACOs still operate by a fee-for-service method; however, incentives will be offered if the ACO can keep costs low. They also must
accept the risk of losing money or being required to hire additional staff or take certain measures if quality and outcome benchmarks are
7
not met. '8 It was then noted that smaller systems may have a harder time than larger systems to enter an ACO due to factors including
pricing and access to the drug and its volume. When observing the increased entrance of oncology drugs into the marketplace, one pharmacist mentioned that value-based medicine has not yet been applied to these medications, but that we are doing it in other cases as
Entresto® (sacubitril/valsartan) has recently been contracted by a value-based model. To summarize the remarks, pharmacy leadership
needs to make the case for pharmacists' engagement within ACOs in the future as the health system continues to transition into valuebased medicine models.
To further expand on the discussion of ACOs, Kaczor provided an example of an ACO by describing Partners For Kids (PFK) at Nationwide
Children's Hospital. Kaczor explained that PFK is fully capitated and responsible for approximately 330,000 covered lives in central and
southeastern Ohio through arrangements with Medicaid Managed Care Organizations. Partners For Kids works with providers to improve
the quality of care while limiting expenses wherever possible, including drug expense. As ACOs expand, Kaczor thinks that the ACOs which
are assuming these risks will need to have a larger voice regarding the payment of high cost drugs. One participant added to this discussion that it could be frustrating to work with certain specialty drugs, like Herceptin® (trastuzumab) and Lunesta® (eszopiclone), with the
limited distribution systems. Another participant offered some advice that it will take time and persistence to work with limited distribution systems. To summarize the discussion on payment models on pharmaceuticals, pharmacist leadership will need to diligently voice
their opinions on ACO regulations and value-based medicine to better manage the expenses of specialty pharmacy.
Next, a pharmacist who works to build specialty pharmacies brought to attention that pharmacists need to take a leadership role to redefine the medications that are entering the specialty pharmacy category. For example, he reminded everyone that medications used to
be identified by their mechanism of action; however, anything that costs over $600 is now considered specialty pharmacy. As one positive
viewpoint on specialty pharmacy, Kaczor suggested that specialty medicines are commonly perceived as high-touch; therefore, pharmacists could justify their clinical services to be reimbursed with the profit earned from these drugs. Overall, specialty pharmacies can be
very successful if pharmacy leadership plans appropriately.
To focus the specialty pharmacy discussion again with a pharmacogenomics perspective, one participant, a previous United States Pharmacopeia expert committee member, mentioned that by the year 2020 there could be a small machine the size of a desktop printer to
print medications personalized to each patient according to their genome. Another participant noted that as one small step toward this
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goal, the first FDA approved printed drug was made in 2015. It was also discussed that in 20 or 30 years, there could be a possibility that
hundreds of medications may be made like this.
As the Summit discussion continued, participants explained that specialty pharmacy was initially designed for clinical care; however, its
utilization may have transitioned due to financial motives over time. Another of the Summit's speakers stressed the need of leadership to
shift the financial focus of specialty pharmacy back to a clinical focus. She noted that this can be achieved by hiring specific clinical pharmacists to develop these new programs since specialty pharmacy requires complex accreditation and reimbursement protocols and a
need for patients to receive appropriate education on those medications.
The discussion on specialty pharmacies eventually moved to the issue of poor integration of information from electronic medical records
(EMR) among health systems. Kaczor spoke of a specialty pharmacy recently started at Nationwide Children's Hospital which services the
cystic fibrosis clinic and agreed that healthcare professionals could experience collective benefits by reporting individual data from various
clinics into an integrated system such as an EMR to comprehensively track patient outcomes. Two individuals guided this conversation to
also address partnerships between providers and payers with pharmacy. Another participant answered that the ACO model's ultimate
goal is to improve quality and communication and to reduce costs and asked of the role of manufacturers with the negotiations of contracts. It was discussed how manufacturers need to be involved in these sorts of discussions such as where rebates fit in with outcomebased contracts. To summarize this conversation, pharmacists need to take leadership roles with ACOs, EM Rs, payers and manufacturers
to provide better integration of data and quality with value-based medicine.
Looking at the utilization of EM Rs in the future, one attendee suggested that EM Rs should be owned by the patient instead of the health
system. Another individual added that it would not be valuable for the patient to own the record until it can be used wherever they go. A
discussion was generated on how professional societies, state boards and colleges could be involved with these decisions. Although the
Summit's participants understand these issues being discussed, the participants were reminded that the average pharmacist may not
understand the details of such complex issues. Solutions will come from advocacy together as a profession.
Lastly, the discussion moved to address drug shortages and drug price increases. One participant posed a specific question on what would
happen if a manufacturer of a certain drug did not receive the contract from a group purchasing organization (GPO) that had 60 percent
of the market. The participant explained his concerns of drug shortages and price increases that may result when only one or two manufacturers for a certain drug face an issue on supplying that drug. To address the issue on drug costs, it was stated that drug costs had been
increasing in a controlled fashion for much of the last decade but, more recently, some drug prices have jumped around threefold. To
address one area of drug shortage management, it was suggested that a professional protocol should be made in regard to the gray market. To understand these issues better, another participant expanded this discussion offering advice on how pharmacy associations can
help, including both at the national and international levels. As an example, she referenced how European pharmacy programs have already implemented value-based medicine programs due to their innovation when facing drug price issues. In the future, pharmacists are
continuously needed in protocol development and pharmacy association involvement.

Reviewing the Key Points
In conclusion, the discussion opened the door for various leaders in pharmacy to address and discuss some of the current issues, goals
and visions within these topics. Specifically, several areas of discussion that were addressed included the management of limited distribution systems; generic drug price escalation; communication between manufacturers, insurance companies and healthcare professionals;
fee-for-service versus value-based medicine; the definition of specialty pharmacy; future use of pharmacogenomic data with pharmaceuticals; improved incorporation of data in EM Rs; new clinical roles for pharmacists within specialty pharmacy; and involvement of local,
state and national pharmacy organizations. With discussions among pharmacists at events such as Ohio Northern University's Health Systems Leadership Summit, the profession of pharmacy will continue to experience beneficial changes in the areas of drug development,
therapeutics and the pharmaceutical marketplace in the future.
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